TOKYO, Feb. 24, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS). HOS specializes in predictive analytics and clinical decision support that enable healthcare organizations to deliver personalized, predictive insights at the point of care, resulting in significant and measurable improvements in clinical, patient and financial outcomes
TOKYO, Feb. 24, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS). HOS specializes in predictive analytics and clinical decision support that enable healthcare organizations to deliver personalized, predictive insights at the point of care, resulting in significant and measurable improvements in clinical, patient and financial outcomes.
Japanese company Terumo Corporation has announced that it has completed the acquisition of Quirem Medical B.V., a Netherlands-based healthcare startup specializing in the development of next-generation microspheres for Selective Internal Radiation Therapy (SIRT), a treatment for liver tumors. Under the terms of the agreement, Terumo acquired 80.1% of the shares of Quirem Medical. This is over and above its current share position of 19.9%, making Quirem Medical now a wholly-owned subsidiary of Terumo.
Orchestra BioMed is partnering up with Terumo to help develop and commercialize its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions. The Virtue angioplasty system is designed to deliver a bioabsorbable, sustained-release formulation of sirolimus directly into the artery wall. The drug helps prevent the vessel from narrowing and reclogging following the placement of a stent or other intervention, a process known as restenosis.
Medical device maker Abbott Laboratories (ABT.N) has offered concessions in an attempt to secure EU antitrust approval for its $25 billion bid for St Jude Medical Inc (STJ.N), according to the European Commision.